Table 1 Patients characteristics, drug treatment, and prophylaxis response
From: Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience
Patient | Sex | Age | Migraine type | NOTCH3 mutation | Daily dose of acetazolamide (mg) | Duration of treatment | Response | Side effects |
|---|---|---|---|---|---|---|---|---|
1 | F | 56 | Without aura | Exon 2 c.194G > A (p.Cys65Tyr) | 250 | 5 months | None | None |
2 | F | 27 | Without aura | Exon 6 c.1012T > C (p.Cys338Arg) | 125 | 6 months | Significant improvement | None |
3 | F | 41 | Without aura | Exon 11 c.1819C > T (p.Arg607Cys) | 250 | 6 months | Significant improvement | None |
4 | F | 48 | With somatosensory aura and aura without headache (language disturbance) | Exon 19 c.3062A > G (p.Tyr1021Cys) | 125 | 6 years (taken only on migraine attack) | Improvement in 1 h | Subjective gastrointestinal disturbance |
5 | F | 68 | Without aura | Exon 11 c.1819 > T (p.Arg607Cys) | 500 | 6 months | None | None |
6 | F | 34 | With visual and somatosensory aura | Exon 11 c.1819 > T (p.Arg607Cys) | 250 | 3 months | Significant improvement | None |
7 | M | 56 | With somatosensory, visual and language disturbances aura | Exon 19 c.3016C > T (p.Arg1006Cys) | 500 | 1 year | Improvement | Mild increase of creatinine levels |